ERC 124

Drug Profile

ERC 124

Alternative Names: Endometrial blood stem cell therapy - Intrexon; Endometrial regenerative cells; ERC-124

Latest Information Update: 03 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MediStem Laboratories; Yale University
  • Developer Brigham and Womens Hospital; ERCell LLC; Intrexon Corporation; Yale University
  • Class Heart failure therapies; Stem cell therapies; Vascular disorder therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Brain injuries; Heart failure; Ischaemia; Peripheral vascular disorders; Type 1 diabetes mellitus

Most Recent Events

  • 03 Oct 2015 No recent reports of development identified - Clinical-Phase-Unknown for Ischaemia in China (IM)
  • 03 Oct 2015 No recent reports of development identified - Phase-II for Heart failure in Russia (Intracoronary)
  • 03 Oct 2015 No recent reports of development identified - Preclinical for Brain injuries in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top